Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

The impact of confounders on the test performance of natriuretic peptides for cardiac dysfunction in subjects aged 80 and older.

Vaes B, Gruson D, Van Pottelbergh G, Pasquet A, Matheï C, Adriaensen W, Rezzoug N, Vanoverschelde JL, Degryse J.

Peptides. 2012 Nov;38(1):118-26. doi: 10.1016/j.peptides.2012.08.020. Epub 2012 Sep 7.

PMID:
22986019
2.

Value of adding natriuretic peptides and electrocardiographic findings to assess the presence of cardiac dysfunction in patients ≥80 years of age.

Vaes B, Boland B, Scavée C, Henrard S, Wallemacq P, Van Pottelbergh G, Matheï C, Pasquet A, Vanoverschelde JL, Rezzoug N, Speybroeck N, Degryse J.

Am J Cardiol. 2013 Apr 15;111(8):1198-208. doi: 10.1016/j.amjcard.2012.12.055. Epub 2013 Feb 1.

PMID:
23375597
3.
4.

Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies.

Codognotto M, Piccoli A, Zaninotto M, Mion M, Plebani M, Vertolli U, Tona F, Ruzza L, Barchita A, Boffa GM.

Clin Chem. 2007 Dec;53(12):2097-104. Epub 2007 Oct 12.

5.

The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.

Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG.

Eur Heart J. 2006 Oct;27(19):2353-61. Epub 2006 Sep 4.

PMID:
16952921
6.

B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients.

Hutcheon SD, Gillespie ND, Struthers AD, McMurdo ME.

Age Ageing. 2002 Jul;31(4):295-301.

PMID:
12147568
7.

Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.

Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr.

Am Heart J. 2005 Apr;149(4):744-50.

PMID:
15990762
8.

Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP.

Chenevier-Gobeaux C, Guerin S, André S, Ray P, Cynober L, Gestin S, Pourriat JL, Claessens YE.

Clin Chem. 2010 Nov;56(11):1708-17. doi: 10.1373/clinchem.2010.145417. Epub 2010 Sep 2.

9.

NT-proBNP and BNP values in cardiac patients with different degree of left ventricular systolic dysfunction.

Kotaska K, Popelova J, Tiserova M, Telekes P, Vrzanova M, Bronsky J, Halacova M, Kukacka J, Prusa R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):125-30.

10.

Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.

Vanderheyden M, Bartunek, Claeys G, Manoharan G, Beckers JF, Ide L.

Clin Biochem. 2006 Jun;39(6):640-5. Epub 2006 Mar 3.

PMID:
16516185
11.
12.

Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, Jensen GB.

Cardiology. 2007;108(1):35-9. Epub 2006 Sep 12.

PMID:
16968988
13.

NT-proBNP: a marker of preclinical cardiac damage in arterial hypertension.

Di Stasio E, Russo A, Mettimano M, Viviani D, Scagliusi A, Bruno A, Giuliani A, Isgrò MA, Romitelli F, Savi L.

Clin Chim Acta. 2011 May 12;412(11-12):1106-11. doi: 10.1016/j.cca.2011.02.035. Epub 2011 Mar 3.

PMID:
21376713
14.

Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.

Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA.

Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96.

PMID:
9373449
15.

Pro-B-type natriuretic peptide levels in acute decompensated heart failure.

Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, Clopton P, Fitzgerald RL, Maisel AS.

J Am Coll Cardiol. 2008 May 13;51(19):1874-82. doi: 10.1016/j.jacc.2007.12.051.

16.

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.

Am J Cardiol. 2008 Sep 15;102(6):733-7. doi: 10.1016/j.amjcard.2008.04.048. Epub 2008 Jul 9.

PMID:
18773998
17.

Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care.

Verdú JM, Comín-Colet J, Domingo M, Lupón J, Gómez M, Molina L, Casacuberta JM, Muñoz MA, Mena A, Bruguera-Cortada J.

Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):613-9. doi: 10.1016/j.recesp.2012.01.019. Epub 2012 Apr 26. English, Spanish.

PMID:
22541282
18.

[Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].

Pokorná V, Jurkovicová O, Kaluzay J, Stecová A, Pont'uch P.

Vnitr Lek. 2010 Aug;56(8):788-94. Slovak.

PMID:
20845610
19.

Age and gender differences in the association between Nt-proBNP and glucometabolic disturbances.

Leosdottir M, Willenheimer R, Hall C, Tjora S, Malm J, Melander O, Nilsson PM.

Scand Cardiovasc J. 2011 Oct;45(5):294-300. doi: 10.3109/14017431.2011.581763. Epub 2011 May 23.

PMID:
21604967
20.

Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers.

Hammerer-Lercher A, Ludwig W, Falkensammer G, Müller S, Neubauer E, Puschendorf B, Pachinger O, Mair J.

Clin Chem. 2004 Jul;50(7):1174-83. Epub 2004 May 13.

Supplemental Content

Support Center